Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The present invention relates to methods and compositions for the treatment of psychiatric disorders such as treatment-resistant depression (TRD) with KCNQ (also known as Kv7) channel openers. Also disclosed is a method of inducing or enhancing resilience in a patient by administration of a KCNQ channel opener, such as ezogabine.

The present invention relates to methods and compositions for the treatment of psychiatric disorders such as treatment-resistant depression (TRD) with KCNQ (also known as Kv7) channel openers. Also disclosed is a method of inducing or enhancing resilience in a patient by administration of a KCNQ channel opener, such as ezogabine.

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound:

##STR00001## wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R.sub.1 and R.sub.2 are independently H— or alkyl; R.sub.3 is H—, alkyl or aralkyl; and R.sub.4 is H— or aryl.

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound:

##STR00001## wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R.sub.1 and R.sub.2 are independently H— or alkyl; R.sub.3 is H—, alkyl or aralkyl; and R.sub.4 is H— or aryl.

A moisturizing lotion composition includes water and propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition. In addition, the moisturizing lotion composition includes aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition, and vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition. In addition, the moisturizing lotion composition includes willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition. Further, the moisturizing lotion composition includes chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition, wherein a ratio of the concentration of the propylene glycol to the concentration of the chamomilla recutita extract is between 4.5 and 5.5.

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.